Rocket Pharmaceuticals Warrant
RCKTW
16 hedge funds and large institutions have $5.39M invested in Rocket Pharmaceuticals Warrant in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1,165% more capital invested
Capital invested by funds: $426K → $5.39M (+$4.96M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 15 → 16 (+1)
0.12% more ownership
Funds ownership: 4.01% → 4.13% (+0.12%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$44K |
| 2 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
+$37.2K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$11.1K |
| 4 |
PVI
Pura Vida Investments
New York
|
+$7.87K |
| 5 |
CS
Clear Street
New York
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$60K |
| 2 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$2.43K |
| 3 |
HF
HRT Financial
New York
|
-$1.63K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$849 |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$754 |
RCKTW Hedge Fund Activity: Q2 2023 in Review
16 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals Warrant (RCKTW) for Q2 2023, worth a combined $5.39M — up 1,165% from $426K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RCKTW positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $44K. The largest seller was Ikarian Capital, exiting entirely with an estimated $60K sold.
- 16 institutional investors held Rocket Pharmaceuticals Warrant (RCKTW) as of Q2 2023, up from 15 in Q1 2023.
- Funds reported $5.39M of Rocket Pharmaceuticals Warrant stock for Q2 2023, up 1,165% quarter-over-quarter.
- 4 funds opened new Rocket Pharmaceuticals Warrant positions in Q2 2023 and 3 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals Warrant buyer in Q2 2023 was Boothbay Fund Management, an estimated $44K added.
- The largest Rocket Pharmaceuticals Warrant seller in Q2 2023 was Ikarian Capital, an estimated $60K sold.
Based on aggregated 13F filings for Q2 2023.